Validation Data Gallery
Tested Applications
Recommended dilution
| Application | Dilution |
|---|---|
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Product Information
85684-6-PBS targets SPINT2/HAI-2 in WB, Indirect ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Recombinant |
| Type | Antibody |
| Immunogen |
CatNo: Eg3130 Product name: Recombinant Human SPINT2/HAI-2 protein (rFc Tag) Source: mammalian cells-derived, V37 Tag: C-rFc Domain: 28-197 aa of NM_021102.3 Sequence: ADRERSIHDFCLVSKVVGRCRASMPRWWYNVTDGSCQLFVYGGCDGNSNNYLTKEECLKKCATVTENATGDLATSRNAADSSVPSAPRRQDSEDHSSDMFNYEEYCTANAVTGPCRASFPRWYFDVERNSCNNFIYGGCRGNKNSYRSEEACMLRCFRQQENPPLPLGSK 相同性解析による交差性が予測される生物種 |
| Full Name | serine peptidase inhibitor, Kunitz type, 2 |
| Calculated molecular weight | 28 kDa |
| Observed molecular weight | 28-34 kDa |
| GenBank accession number | NM_021102.3 |
| Gene Symbol | SPINT2 |
| Gene ID (NCBI) | 10653 |
| Conjugate | Unconjugated |
| Form | |
| Form | Liquid |
| Purification Method | Protein A purification |
| UNIPROT ID | O43291-1 |
| Storage Buffer | PBS only{{ptg:BufferTemp}}7.3 |
| Storage Conditions | Store at -80°C. |
Background Information
Serine peptidase inhibitor Kunitz type 2 (SPINT2) is a serine protease inhibitor Kunitz type 2, also known as hepatocyte growth factor (HGF) activator (HGFA) inhibitor type 2 (HAI-2). It displays inhibitory activity in membrane serine proteases, such as matriptase and hepsin, as well as secreted proteases such as HGFA and plasmin (PMID: 9771903, PMID: 15792801). SPINT2 is a tumor suppressor gene that inhibits proteases implicated in cancer progression, like HGFA, hepsin and matriptase (PMID: 30168196). SPINT2 regulates cell proliferation, migration and invasion via a reduction in HGFA, leading to apoptosis and necrosis of uterine leiomyosarcoma cells (PMID: 20664929). This target may exhibit a molecular weight of approximately 28-34 kDa due to glycosylation modification.